Home
CLNN
CLNN News

Latest Clene Inc. (CLNN) News on September 16, 2025

Q2 Virtual Investor Summit: Presentations Available Now

ACCESS Newswire

3 months ago

Q2 Virtual Investor Summit: Presentations Available Now

When Will Clene Inc. (NASDAQ:CLNN) Breakeven?

Simply Wall St.

3 months ago

When Will Clene Inc. (NASDAQ:CLNN) Breakeven?

ACCESS Newswire

3 months ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

GlobeNewswire

4 months ago

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

Newsfile

4 months ago

Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

GlobeNewswire

4 months ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

GlobeNewswire

5 months ago

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Clene to Present at the Emerging Growth Conference

GlobeNewswire

5 months ago

Clene to Present at the Emerging Growth Conference

Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session

GlobeNewswire

5 months ago

Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session

Clene to Present at the Jones Healthcare and Technology Innovation Conference

GlobeNewswire

5 months ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025

NewMediaWire

6 months ago

Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

GlobeNewswire

6 months ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Bullish Clene Insiders Loaded Up On US$583.4k Of Stock

Simply Wall St.

6 months ago

Bullish Clene Insiders Loaded Up On US$583.4k Of Stock

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

ACCESS Newswire

6 months ago

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

GlobeNewswire

6 months ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Clene to Present at the 37TH Annual Roth Conference

GlobeNewswire

6 months ago

Clene to Present at the 37TH Annual Roth Conference

ACCESS Newswire

7 months ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction

GlobeNewswire

7 months ago

Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction

Is Clene Inc. (CLNN) the Best Nanotech Penny Stock to Invest In?

Insider Monkey

7 months ago

Is Clene Inc. (CLNN) the Best Nanotech Penny Stock to Invest In?

IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

NewMediaWire

8 months ago

IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)

NewMediaWire

9 months ago

IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)

IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments

NewMediaWire

9 months ago

IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments

Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan

GlobeNewswire

9 months ago

Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan

IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway

NewMediaWire

9 months ago

IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

GlobeNewswire

9 months ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Clene price target lowered to $83 from $86 at Canaccord

TipRanks

10 months ago

Clene price target lowered to $83 from $86 at Canaccord

Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights

GlobeNewswire

10 months ago

Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights

IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership

IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences

IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements

IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences

Clene to Present at Upcoming October Conferences

GlobeNewswire

a year ago

Clene to Present at Upcoming October Conferences

Independent Chairman of the Board of Clene David Matlin Buys 26% More Shares

Simply Wall St.

a year ago

Independent Chairman of the Board of Clene David Matlin Buys 26% More Shares

IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M

IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements

Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility

GlobeNewswire

a year ago

Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

GlobeNewswire

a year ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

GlobeNewswire

a year ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

IBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment Conference

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment Conference

IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

a year ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast

IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials

NewMediaWire

a year ago

IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials

IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions

IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode

IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates

NewMediaWire

a year ago

IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

GlobeNewswire

a year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

GlobeNewswire

a year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS

GlobeNewswire

a year ago

Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS

Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

GlobeNewswire

a year ago

Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

Clene to Present at the Emerging Growth Conference

GlobeNewswire

a year ago

Clene to Present at the Emerging Growth Conference

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

GlobeNewswire

a year ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Clene Announces 1-for-20 Reverse Stock Split

GlobeNewswire

a year ago

Clene Announces 1-for-20 Reverse Stock Split

Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference

GlobeNewswire

a year ago

Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

GlobeNewswire

a year ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

GlobeNewswire

a year ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now

Better AI Stock: Palantir vs. Snowflake

Motley Fool

a year ago

Better AI Stock: Palantir vs. Snowflake

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

Motley Fool

a year ago

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

BigBear.ai Stock: Buy, Sell, or Hold?

Motley Fool

a year ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'

AFP

a year ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?

Motley Fool

a year ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

GuruFocus.com

a year ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

GuruFocus.com

a year ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

Simply Wall St.

a year ago

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

Clene to Present at the Emerging Growth Conference

GlobeNewswire

a year ago

Clene to Present at the Emerging Growth Conference

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

GlobeNewswire

a year ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

Clene to Present at Upcoming May Conferences

GlobeNewswire

a year ago

Clene to Present at Upcoming May Conferences

Clene First Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Clene First Quarter 2024 Earnings: Misses Expectations

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

GlobeNewswire

a year ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington

GlobeNewswire

a year ago

IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington

Bullish Clene Insiders Loaded Up On US$9.58m Of Stock

Simply Wall St.

a year ago

Bullish Clene Insiders Loaded Up On US$9.58m Of Stock

Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

GlobeNewswire

a year ago

Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington

GlobeNewswire

a year ago

IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

GlobeNewswire

2 years ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

GlobeNewswire

2 years ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Clene to Present at the 36th Annual ROTH Conference

GlobeNewswire

2 years ago

Clene to Present at the 36th Annual ROTH Conference

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

GlobeNewswire

2 years ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs

GlobeNewswire

2 years ago

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs

Clene Inc. announces positive results from CNM-Au8 results from MS trial

News Direct

2 years ago

Clene Inc. announces positive results from CNM-Au8 results from MS trial

Inogen to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Business Wire

2 years ago

Inogen to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

TEAF Announces 2023 Fund Tax Characterization of Distributions, Release of Annual Report

ACCESSWIRE

2 years ago

TEAF Announces 2023 Fund Tax Characterization of Distributions, Release of Annual Report

Princeton Bancorp (BPRN) Q4 Earnings Surpass Estimates

Zacks

2 years ago

Princeton Bancorp (BPRN) Q4 Earnings Surpass Estimates

Inogen Names Michael Bourque as New Chief Financial Officer

Business Wire

2 years ago

Inogen Names Michael Bourque as New Chief Financial Officer

Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment

NewMediaWire

2 years ago

Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment

Delcath Systems, Inc. (NASDAQ:DCTH): Are Analysts Optimistic?

Simply Wall St.

2 years ago

Delcath Systems, Inc. (NASDAQ:DCTH): Are Analysts Optimistic?

Trump Shakes Iowa: Discover the 3 Hot Stocks Set to Soar in His Wake

Benzinga

2 years ago

Trump Shakes Iowa: Discover the 3 Hot Stocks Set to Soar in His Wake

American Battery Technology Company Announces Increased and Upgraded Lithium Resource to Measured and Indicated Classifications for One of the Largest Lithium Projects in the United States

PR Newswire

2 years ago

American Battery Technology Company Announces Increased and Upgraded Lithium Resource to Measured and Indicated Classifications for One of the Largest Lithium Projects in the United States

Nutex Health Inc.'s (NASDAQ:NUTX) top owners are retail investors with 47% stake, while 43% is held by insiders

Simply Wall St.

2 years ago

Nutex Health Inc.'s (NASDAQ:NUTX) top owners are retail investors with 47% stake, while 43% is held by insiders

RADCOM to Report Fourth Quarter and Full Year 2023 Results on January 31, 2024

PR Newswire

2 years ago

RADCOM to Report Fourth Quarter and Full Year 2023 Results on January 31, 2024

Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program

GlobeNewswire

2 years ago

Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program

Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial

NewMediaWire

2 years ago

Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial

Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension

GlobeNewswire

2 years ago

Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension

Clough Global Equity Fund Declares Monthly Cash Distributions For January, February, and March 2024 of $0.0603 Per Share

ACCESSWIRE

2 years ago

Clough Global Equity Fund Declares Monthly Cash Distributions For January, February, and March 2024 of $0.0603 Per Share

Business Wire

2 years ago

Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

GlobeNewswire

2 years ago

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3

NewMediaWire

2 years ago

Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3

Share on Social Networks: